GMAB (Genmab AS) Earnings per share for the last four quarters

Public company logo of Genmab AS (GMAB)

Genmab A/S maximizes the delegation of production and testing to external contractors, focusing instead on antibody development. This daily price action of the rolling EPS YoY change displayed on GURU.Markets demonstrates business inertia, where -50.60 serves as the current metric level. High-yield targeted drugs drive revolutionary growth, while inelastic demand for oncology therapies guarantees stable cash flows through royalties.

GMAB genmab.com Earnings per share for the last twelve months (02/11/2024 - 11/12/2026)

Genmab US - analytical breakdowns and key metrics (GMAB)

- current price and projected stock value:
Price Performance Chart genmab.com|GMAB - Consensus Target
- business market valuation indicators:
Market Value Genmab AS|GMAB - Enterprise Value
- business book valuation details:
Book Value per Share Genmab|GMAB - Company Book Value|Market Value to Book Value genmab.com|GMAB - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio Genmab A/S|GMAB - Long-Term Debt to Capital|Current Liabilities to Capital Genmab Corp|GMAB - Company Total Debt|Debt to Book Capital Genmab AS|GMAB - Company Long-Term Debts|Short-Term Debt Genmab|Immediate Liquidity Ratio genmab.com
- earnings and multiples data:
GMAB - Net Income|Expected Net Income Genmab A/S|GMAB - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Genmab AS|GMAB - PEG Multiple|Business Value to Operating Income Before Depreciation Genmab AS|GMAB - Operating profit EBITDA|Net earnings per one share for the last twelve months Genmab|GMAB - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months genmab.com|GMAB - Earnings growth in current year|Earnings growth forecast for next year Genmab A/S
Fundamental valuation:genmab.com (GMAB)
Signature product of Genmab

Genmab A/S minimizes capital expenditures by outsourcing production and clinical trials to third-party contractors. Analyzing the trailing twelve months (TTM) net income per share growth rate allows for an assessment of the efficiency of this asset-light business model. This metric measures profit dynamics over the last 12 months, revealing the actual pace of business scaling. It is critical for investors to monitor any deceleration in this growth to timely recognize the risk of asset overvaluation.

Competitor analysis for Genmab A/S

Earnings per share for the trailing year EXEL (exelixis.com)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Bio) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Enliven Corp|Earnings per share for the last twelve months ORIC Pharmaceuticals (ORIC)|RLAY (relaytx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics, Inc.)|Net earnings per share for the trailing year Tyra Biosciences Inc|Verastem Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Corp|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (C4 Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics, Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc - Earnings per share for the last 12 months|Karyopharm Therapeutics Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|Aadi Bioscience - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corporation - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months springworkstx.com SWTX